ACADIA Pharmaceuticals Inc. (ACAD) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ACAD Revenue Growth
Revenue Breakdown (FY 2018)
ACAD's revenue distribution by segment and geography for fiscal year 2018
By Product/Segment
ACAD Revenue Analysis (2014–2025)
As of May 8, 2026, ACADIA Pharmaceuticals Inc. (ACAD) generated trailing twelve-month (TTM) revenue of $1.10 billion, reflecting solid growth of +9.7% year-over-year. The most recent quarter (Q1 2026) recorded $268.1 million in revenue, down 5.6% sequentially.
Looking at the longer-term picture, ACAD's 5-year compound annual growth rate (CAGR) stands at +19.4%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $1.07 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows ACAD's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INVA (+13.6% YoY), AXSM (+63.9% YoY), and INTR, ACAD has underperformed the peer group in terms of revenue growth. Compare ACAD vs INVA →
ACAD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ACADCurrent | $1.1B | +9.7% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 INTR | $14.6B | - | - | 10.9% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% |
ACAD Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.07B | +11.9% | $982.5M | 91.7% | $104.8M | 9.8% |
| 2024 | $957.8M | +31.8% | $876.0M | 91.5% | $230.8M | 24.1% |
| 2023 | $726.4M | +40.4% | $680.7M | 93.7% | $-73,379,000 | -10.1% |
| 2022 | $517.2M | +6.8% | $507.1M | 98.0% | $-223,596,000 | -43.2% |
| 2021 | $484.1M | +9.6% | $465.0M | 96.0% | $-170,439,000 | -35.2% |
| 2020 | $441.8M | +30.3% | $421.2M | 95.3% | $-286,586,000 | -64.9% |
| 2019 | $339.1M | +51.5% | $319.5M | 94.2% | $-246,545,000 | -72.7% |
| 2018 | $223.8M | +79.2% | $205.5M | 91.8% | $-247,444,000 | -110.6% |
| 2017 | $124.9M | +620.7% | $111.8M | 89.5% | $-292,410,000 | -234.1% |
| 2016 | $17.3M | +28311.5% | $12.9M | 74.6% | $-272,815,000 | -1574.1% |
See ACAD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACAD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACAD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
Is ACAD's revenue growth accelerating or slowing?
ACAD maintains +9.7% revenue growth, in line with its 5-year CAGR of +19.4%. TTM revenue stands at $1.1B. Growth rate remains consistent with historical average.
What is ACAD's long-term revenue growth rate?
ACADIA Pharmaceuticals Inc.'s 5-year revenue CAGR of +19.4% reflects the sustained expansion pattern. Current YoY growth of +9.7% is near this long-term average.
How is ACAD's revenue distributed by segment?
ACAD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.